New hope for myeloma patients: epunamin combo under study
NCT ID NCT07497165
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether adding the drug epunamin to a standard chemotherapy regimen (DECP) can help people with relapsed or refractory multiple myeloma, a type of blood cancer that has not responded to previous treatments. The study will enroll 48 adults aged 18 to 75 and track how many achieve a meaningful reduction in cancer cells after four treatment cycles. It is a real-world study, meaning it observes what happens in everyday clinical practice rather than in a strictly controlled lab setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
epunamin combined with a DECP-based chemotherapy regimen
What this could lead to
If successful, this could offer a new treatment option for people with multiple myeloma that has stopped responding to standard therapies.
What could go wrong
This is a small, early-stage real-world study with no comparison group, so results may not be conclusive. The combination may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ShanxiBethuneH
RECRUITINGTaiyuan, Shanxi, 030000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••